2 September 2010 – Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced that it has observed efficacy in a model of Alzheimer’s disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011.“Specifically targeting the signaling of the neurotransmitter glutamate using mGluR2 NAM is one of the most promising avenues of research for treating cognitive symptoms of Alzheimer’s disease... Addex Pharmaceuticals' Press Release -
